Loading...
•
Mar 31, 2023
Innoviva Q1 2023 Earnings Report
Reported strong revenues from royalty and product portfolios, executed key corporate objectives and FDA advisory committee voted in support of sulbactam-durlobactam approval.
Key Takeaways
Innoviva reported strong Q1 2023 results with significant revenue from royalties and product sales. Net income increased to $34.9 million, and the company repurchased $40.3 million in common stock and paid off $96.2 million in convertible notes.
Received $60.3 million in GSK royalties, $11.5 million in net product revenues, and $8.0 million in license revenue.
Repurchased $40.3 million of common stock and paid off $96.2 million of 2023 convertible notes.
Net income was $34.9 million, or $0.51 basic per share.
Cash and cash equivalents totaled $144.0 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...